PTEN and neoplasm: In AD, one study reported that it acts as an oncogene by suppressing SOCS1 and PTEN tumor suppressors, leading to activated JAK/STAT and PI3K signaling pathways that drive tumor growth and correlate with poor patient outcomes [43].